01 1Pomalyst /Imnovid
02 5Pomalyst/Imnovid
03 3Pomalyst/Imnovid
04 1Pomalyst/Imnovid - BMS
05 1Pomalyst/Imnovid - Celgene
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 3,070
2019 Revenue in Millions : 2,162
Growth (%) : 42
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 3,332
2020 Revenue in Millions : 3,070
Growth (%) : 9
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 3,497
2021 Revenue in Millions : 3,332
Growth (%) : 5
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 3,441
2022 Revenue in Millions : 3,497
Growth (%) : -2
Main Therapeutic Indication : Oncology
Currency : USD
2015 Revenue in Millions : 680
2014 Revenue in Millions : 983
Growth (%) : 45%
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 1,614
2016 Revenue in Millions : 1,311
Growth (%) : 23
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 1,311
2015 Revenue in Millions : 983
Growth (%) : 33
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 2,040
2017 Revenue in Millions : 1,614
Growth (%) : 26%
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 322
2018 Revenue in Millions : 0
Growth (%) : N/A
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 1,840
2018 Revenue in Millions : 2,040
Growth (%) : N/A
LOOKING FOR A SUPPLIER?